Stock Market & Financial Investment News

InterMune reports preliminary Q4 Esbriet revenue $25.6M vs. $8.2M a year agoReports FY13 Esbriet revenue approximately $70.2M. Sees FY14 Esbriet revenue up 65%-90% to $115M-$135M. The company also comments "Our European operations are performing well and we expect cash flows from our European sales to fully support our European operations sometime in the latter half of 2014...Today, we announced that we expect to communicate top-line results from the ASCEND study early in 2Q14, and to present the study results at the American Thoracic Society conference in May." In 2014: The company expects to continue its growth of Esbriet revenue in the 13 of 15 targeted countries in which Esbriet has now been launched. InterMune expects to have further information on the status of pricing and reimbursement of Esbriet in Spain and the Netherlands in the first half of 2014. In late 2014, the company expects to begin commercializing Esbriet in other countries beyond its initial EU priority 15 countries. InterMune currently has 170 employees in Europe and expects to expand its European commercial infrastructure to between 190 and 220 employees by the end of 2014 depending upon the need to support potential launches in Spain, the Netherlands and additional European countries beyond the initial first-priority 15 countries. InterMune currently expects to report top-line results from ASCEND early in the second quarter of 2014 and to present study results at the May 2014 International Conference of the American Thoracic Society in San Diego. The company plans to provide a timeline for the Esbriet NDA resubmission when it announces the top-line results of ASCEND in the second quarter of 2014.